[go: up one dir, main page]

AR090371A1 - Forma cristalina - Google Patents

Forma cristalina

Info

Publication number
AR090371A1
AR090371A1 ARP130100880A ARP130100880A AR090371A1 AR 090371 A1 AR090371 A1 AR 090371A1 AR P130100880 A ARP130100880 A AR P130100880A AR P130100880 A ARP130100880 A AR P130100880A AR 090371 A1 AR090371 A1 AR 090371A1
Authority
AR
Argentina
Prior art keywords
crystalline form
carbonylimino
benzenesulfonylamino
pyrazine
diamino
Prior art date
Application number
ARP130100880A
Other languages
English (en)
Inventor
Howsham Catherine
Lindenberg Christian
Perlberg Anett
Tufilli Nicola
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48237169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR090371(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR090371A1 publication Critical patent/AR090371A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente se relaciona con una forma cristalina de la sal de succinato del bloqueador de canales de sodio epitelial (ENaC), el éster dipropilcarbamoilmetilo del ácido 3-(3-{2-[(E)-3,5-diamino-6-cloro-pirazina-2-carbonilimino]-1,3,8-triaza-espiro[4.5]decano-8-carbonil}-bencenosulfonilamino)-propiónico, composiciones farmacéuticas que comprenden dicha forma cristalina, usos de dicha forma cristalina y composiciones farmacéuticas, y métodos para preparar dicha forma cristalina. Reivindicación 1: Una forma cristalina de succinato de éster dipropilcarbamoilmetilo del ácido 3-(3-{2-[(E)-3,5-diamino-6-cloro-pirazina-2-carbonilimino]-1,3,8-triaza-espiro[4.5]decano-8-carbonil}-bencenosulfonilamino)-propiónico de fórmula (1) que comprende la forma C.
ARP130100880A 2012-03-19 2013-03-19 Forma cristalina AR090371A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261612727P 2012-03-19 2012-03-19

Publications (1)

Publication Number Publication Date
AR090371A1 true AR090371A1 (es) 2014-11-05

Family

ID=48237169

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130100880A AR090371A1 (es) 2012-03-19 2013-03-19 Forma cristalina

Country Status (34)

Country Link
US (1) US8809340B2 (es)
EP (1) EP2828261B1 (es)
JP (1) JP6134378B2 (es)
KR (1) KR101686311B1 (es)
CN (1) CN104302648B (es)
AR (1) AR090371A1 (es)
AU (1) AU2013237073B2 (es)
CA (1) CA2865536C (es)
CL (1) CL2014002339A1 (es)
CO (1) CO7071138A2 (es)
CY (1) CY1117410T1 (es)
DK (1) DK2828261T3 (es)
EA (1) EA023716B1 (es)
EC (1) ECSP14023397A (es)
ES (1) ES2565811T3 (es)
GT (1) GT201400200A (es)
HR (1) HRP20160420T1 (es)
HU (1) HUE028761T2 (es)
IN (1) IN2014DN07461A (es)
JO (1) JO3184B1 (es)
MA (1) MA37391B1 (es)
MX (1) MX352185B (es)
MY (1) MY165082A (es)
NZ (1) NZ629032A (es)
PE (1) PE20142352A1 (es)
PH (1) PH12014502064B1 (es)
PL (1) PL2828261T3 (es)
SG (1) SG11201405105TA (es)
SI (1) SI2828261T1 (es)
TN (1) TN2014000369A1 (es)
TW (1) TWI608006B (es)
UA (1) UA114904C2 (es)
WO (1) WO2013140319A1 (es)
ZA (1) ZA201406238B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2774814B2 (ja) 1989-05-15 1998-07-09 三菱化学ビーエーエスエフ株式会社 高弾性の熱可塑性樹脂発泡成形品の製造方法
CA2635581C (en) 2005-12-28 2017-02-28 Vertex Pharmaceuticals Incorporated Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US9050339B2 (en) 2010-09-17 2015-06-09 Novartis Ag Pyrazine derivatives as ENaC blockers
CA2963945C (en) 2014-10-07 2023-01-10 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219606A (en) 1968-07-15 1971-01-20 Rech S Et D Applic Scient Soge Quinuclidinol derivatives and preparation thereof
IT1016489B (it) 1974-03-18 1977-05-30 Isf Spa Inalatore
JPS6235216A (ja) 1985-08-09 1987-02-16 Noritoshi Nakabachi 不均質物質層の層厚非破壊測定方法および装置
GB8923590D0 (en) 1989-10-19 1989-12-06 Pfizer Ltd Antimuscarinic bronchodilators
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
PT100441A (pt) 1991-05-02 1993-09-30 Smithkline Beecham Corp Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso
WO1993018007A1 (fr) 1992-03-13 1993-09-16 Tokyo Tanabe Company Limited Nouveau derive de carbostyrile
HU225869B1 (en) 1992-04-02 2007-11-28 Smithkline Beecham Corp Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them
JP3251587B2 (ja) 1992-04-02 2002-01-28 スミスクライン・ビーチャム・コーポレイション 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物
WO1993019750A1 (en) 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
US6596260B1 (en) 1993-08-27 2003-07-22 Novartis Corporation Aerosol container and a method for storage and administration of a predetermined amount of a pharmaceutically active aerosol
US6051397A (en) 1993-11-16 2000-04-18 Max Planck Gesellschaft Zur Forderung Der Wissenschaften DNA encoding MCK-10, a novel receptor tyrosine kinase
US6182655B1 (en) 1995-12-07 2001-02-06 Jago Research Ag Inhaler for multiple dosed administration of a pharmacological dry powder
ATE209939T1 (de) 1996-01-03 2001-12-15 Glaxo Group Ltd Inhalator
RU2195965C2 (ru) 1996-02-21 2003-01-10 Шеринг Корпорейшн Устройство для ингаляции порошка
GB9622386D0 (en) 1996-10-28 1997-01-08 Sandoz Ltd Organic compounds
US6166037A (en) 1997-08-28 2000-12-26 Merck & Co., Inc. Pyrrolidine and piperidine modulators of chemokine receptor activity
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
CA2335094C (en) 1998-06-30 2008-12-23 The Dow Chemical Company Polymer polyols and a process for the production thereof
GB9913083D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
SK286968B6 (sk) 1999-05-04 2009-08-06 Schering Corporation Piperidín-piperidinyl ako CCR5 antagonista, farmaceutický prostriedok s jeho obsahom a jeho použitie
WO2000066558A1 (en) 1999-05-04 2000-11-09 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
US6683115B2 (en) 1999-06-02 2004-01-27 Theravance, Inc. β2-adrenergic receptor agonists
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
AU777012B2 (en) 1999-08-21 2004-09-30 Takeda Gmbh Synergistic combination of PDE inhibitors and beta 2 adrenoceptor agonist
OA11558A (en) 1999-12-08 2004-06-03 Advanced Medicine Inc Beta 2-adrenergic receptor agonists.
WO2003000840A2 (en) 2001-06-21 2003-01-03 Diversa Corporation Nitrilases
US7069929B2 (en) 2000-02-01 2006-07-04 Quadrant Technologies Limited Dry powder inhaler
WO2001083462A1 (de) 2000-04-27 2001-11-08 Boehringer Ingelheim Pharma Kg Neue, langwirksame betamimetika, verfahren zu deren herstellung und deren verwendung als arzneimittel
DK1300407T4 (da) 2000-06-27 2011-09-05 S A L V A T Lab Sa Carbamater afledt af arylalkylaminer
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
DE10038639A1 (de) 2000-07-28 2002-02-21 Schering Ag Nichtsteroidale Entzündungshemmer
KR100889426B1 (ko) 2000-08-05 2009-03-23 글락소 그룹 리미티드 항염증제로서의 6.알파.,9.알파.-디플루오로-17.알파.-'(2-푸라닐카르복실)옥시-11.베타.-히드록시-16.알파.-메틸-3-옥소-안드로스트-1,4-디엔-17-카르보티오산 ｓ-플루오로메틸 에스테르
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
ATE305468T1 (de) 2000-12-22 2005-10-15 Almirall Prodesfarma Ag Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
SI1353919T1 (sl) 2000-12-28 2006-12-31 Almirall Prodesfarma Ag Novi derivati kinuklidina in medicinske zmesi, kijih vsebujejo.
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ　グループ　リミテッド βアドレナリン受容体のアゴニスト
ATE381537T1 (de) 2001-03-22 2008-01-15 Glaxo Group Ltd Formanilid-derivative als beta2-adrenorezeptor- agonisten
AU2002253342B2 (en) 2001-04-30 2007-01-04 Glaxo Group Limited Novel anti-inflammatory androstane derivatives
JP2005500290A (ja) 2001-06-12 2005-01-06 グラクソ　グループ　リミテッド 抗炎症性の、１７β−カルボチオアートアンドロスタン誘導体である１７α複素環エステル
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
CA2462980A1 (en) 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
GB0125259D0 (en) 2001-10-20 2001-12-12 Glaxo Group Ltd Novel compounds
AR037517A1 (es) 2001-11-05 2004-11-17 Novartis Ag Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
WO2003042160A1 (en) 2001-11-13 2003-05-22 Theravance, Inc. Aryl aniline beta-2 adrenergic receptor agonists
AU2002356759A1 (en) 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
PL211250B1 (pl) 2001-12-20 2012-04-30 Chiesi Farma Spa Pochodne karbaminianu 1-alkilo-1-azoniabicyklo [2.2.2] oktanu, jej zastosowania, kompozycja farmaceutyczna zawierająca ten związek oraz związek pośredni
WO2003072592A1 (en) 2002-01-15 2003-09-04 Glaxo Group Limited 17.alpha-cycloalkyl/cycloylkenyl esters of alkyl-or haloalkyl-androst-4-en-3-on-11.beta.,17.alpha.-diol 17.beta.-carboxylates as anti-inflammatory agents
WO2003062259A2 (en) 2002-01-21 2003-07-31 Glaxo Group Limited Non-aromatic 17.alpha.-esters of androstane-17.beta.-carboxylate esters as anti-inflammatory agents
GB0202216D0 (en) 2002-01-31 2002-03-20 Glaxo Group Ltd Novel compounds
GB0204719D0 (en) 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
US7268152B2 (en) 2002-03-26 2007-09-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
KR101022977B1 (ko) 2002-03-26 2011-03-18 베링거 인겔하임 파마슈티칼즈, 인코포레이티드 글루코코르티코이드 모사체, 이의 제조방법, 약제학적조성물 및 이의 용도
US7282591B2 (en) 2002-04-11 2007-10-16 Merck & Co., Inc. 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ATE381535T1 (de) 2002-04-25 2008-01-15 Glaxo Group Ltd Phenethanolaminderivate
EP1507754A1 (en) 2002-05-28 2005-02-23 Theravance, Inc. Alkoxy aryl beta-2 adrenergic receptor agonists
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
ES2201907B1 (es) 2002-05-29 2005-06-01 Almirall Prodesfarma, S.A. Nuevos derivados de indolilpiperidina como potentes agentes antihistaminicos y antialergicos.
DE10224888A1 (de) 2002-06-05 2003-12-24 Merck Patent Gmbh Pyridazinderivate
US7074806B2 (en) 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
DE10225574A1 (de) 2002-06-10 2003-12-18 Merck Patent Gmbh Aryloxime
DE10227269A1 (de) 2002-06-19 2004-01-08 Merck Patent Gmbh Thiazolderivate
US7153968B2 (en) 2002-06-25 2006-12-26 Merck Frosst Canada, Ltd. 8-(biaryl)quinoline PDE4 inhibitors
CA2490097A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
BR0312575A (pt) 2002-07-08 2005-05-03 Pfizer Prod Inc Moduladores do receptor de glicocorticóides
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
PE20050130A1 (es) 2002-08-09 2005-03-29 Novartis Ag Compuestos organicos
AU2003255376A1 (en) 2002-08-10 2004-03-11 Altana Pharma Ag Piperidine-derivatives as pde4 inhibitors
EP1556369A1 (en) 2002-08-10 2005-07-27 ALTANA Pharma AG Pyridazinone-derivatives as pde4 inhibitors
PL373597A1 (en) 2002-08-10 2005-09-05 Altana Pharma Ag Piperidine-n-oxide-derivatives
ATE360627T1 (de) 2002-08-10 2007-05-15 Altana Pharma Ag Pyrrolidindion-substituierte piperidin- phthalazone als pde4-inhibitoren
WO2004018465A2 (en) 2002-08-17 2004-03-04 Altana Pharma Ag Benzonaphthyridines with pde 3/4 inhibiting activity
EP1537086A2 (en) 2002-08-17 2005-06-08 ALTANA Pharma AG Novel phenanthridines
SE0202483D0 (sv) 2002-08-21 2002-08-21 Astrazeneca Ab Chemical compounds
DE60322713D1 (de) 2002-08-21 2008-09-18 Boehringer Ingelheim Pharma Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
EP1534675B1 (en) 2002-08-23 2009-02-25 Ranbaxy Laboratories, Ltd. Fluoro and sulphonylamino containing 3,6-disubstituted azabicyclo¬3.1.0 hexane derivatives as muscarinic receptor antagonists
EP1539164B1 (en) 2002-08-29 2006-12-20 ALTANA Pharma AG 2-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
DE60333371D1 (de) 2002-08-29 2010-08-26 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indol-derivate zur verwendung als glucocorticoid-mimetika bei der behandlung von entzündlichen, allergischen und proliferativen erkrankungen
EP1536798B1 (en) 2002-08-29 2007-02-07 ALTANA Pharma AG 3-hydroxy-6-phenylphenanthridines as pde-4 inhibitors
GB0220730D0 (en) 2002-09-06 2002-10-16 Glaxo Group Ltd Medicinal compounds
JP2006096662A (ja) 2002-09-18 2006-04-13 Sumitomo Pharmaceut Co Ltd 新規６−置換ウラシル誘導体及びアレルギー性疾患の治療剤
BR0314304A (pt) 2002-09-18 2005-07-26 Ono Pharmaceutical Co Drogas e derivados de triazapiro[5.5]undecano compreendendo o mesmo como o ingrediente ativo
JP2004107299A (ja) 2002-09-20 2004-04-08 Japan Energy Corp 新規１−置換ウラシル誘導体及びアレルギー性疾患の治療剤
JP4520309B2 (ja) 2002-09-20 2010-08-04 メルク・シャープ・エンド・ドーム・コーポレイション 選択的糖質コルチコイド受容体調節剤としてのオクタヒドロ−２−Ｈ−ナフト［１，２−ｆ］インドール−４−カルボキサミド誘導体
DE10246374A1 (de) 2002-10-04 2004-04-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika mit verlängerter Wirkungsdauer, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1440966A1 (en) 2003-01-10 2004-07-28 Pfizer Limited Indole derivatives useful for the treatment of diseases
ES2302938T3 (es) 2002-10-11 2008-08-01 Pfizer Inc. Derivados de indol como agonistas beta-2.
JP2006506373A (ja) 2002-10-22 2006-02-23 グラクソ　グループ　リミテッド 医薬アリールエタノールアミン化合物
PL376769A1 (pl) 2002-10-23 2006-01-09 Glenmark Pharmaceuticals Ltd. Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
AU2003286143A1 (en) 2002-10-28 2004-05-13 Glaxo Group Limited Phenethanolamine derivative for the treatment of respiratory diseases
GB0225030D0 (en) 2002-10-28 2002-12-04 Glaxo Group Ltd Medicinal compounds
GB0225287D0 (en) 2002-10-30 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
GB0225535D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
DE10253282A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung
DE10253220A1 (de) 2002-11-15 2004-05-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Dihydroxy-Methyl-Phenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE10253426B4 (de) 2002-11-15 2005-09-22 Elbion Ag Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phosphodiesterase 4 und Verfahren zu deren Herstellung
DE10261874A1 (de) 2002-12-20 2004-07-08 Schering Ag Nichtsteroidale Entzündungshemmer
JP4606408B2 (ja) 2003-01-21 2011-01-05 メルク・シャープ・エンド・ドーム・コーポレイション 選択的グルココルチコイド受容体調節物質としての１７−カルバモイルオキシコルチゾル誘導体
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
US20050113423A1 (en) 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
EP1460064A1 (en) 2003-03-14 2004-09-22 Pfizer Limited Indole-2-carboxamide derivatives useful as beta-2 agonists
WO2004110352A2 (en) 2003-05-16 2004-12-23 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
GB0312832D0 (en) 2003-06-04 2003-07-09 Pfizer Ltd 2-amino-pyridine derivatives useful for the treatment of diseases
EP1646615B1 (en) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
EP1636269A2 (en) 2003-06-10 2006-03-22 Ace Biosciences A/S Extracellular aspergillus polypeptides
AU2004272599A1 (en) 2003-09-06 2005-03-24 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
JP2007509044A (ja) 2003-10-08 2007-04-12 バーテックス　ファーマシューティカルズ　インコーポレイテッド シクロアルキルピラニル基を含むａｔｐ結合カセットトランスポーターのモジュレータ
GB2407042B (en) 2003-10-17 2007-10-24 Vectura Ltd Inhaler
US7541466B2 (en) 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
CN1938279B (zh) 2004-01-30 2011-09-14 沃泰克斯药物股份有限公司 Atp-结合弹夹转运蛋白调控剂
BRPI0507884A (pt) 2004-02-24 2007-08-07 Microdose Technologies Inc método e equipamento para administração de medicamento com base em jato sintético
GB0410712D0 (en) 2004-05-13 2004-06-16 Novartis Ag Organic compounds
AU2005251745A1 (en) 2004-06-04 2005-12-22 The Regents Of The University Of California Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
WO2006099256A2 (en) 2005-03-11 2006-09-21 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
AU2006227833A1 (en) 2005-03-18 2006-09-28 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
JP5426878B2 (ja) 2005-05-24 2014-02-26 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｐ−結合カセットトランスポーターのモジュレーター
CA2618057A1 (en) 2005-08-11 2007-02-22 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
MX2009004349A (es) 2006-10-25 2009-07-22 Novartis Ag Aparato de dispersion de polvo, metodo para hacer y usar el aparato, y componentes que se pueden usar en el aparato y otros dispositivos.
AR069637A1 (es) 2007-12-10 2010-02-10 Novartis Ag Derivados de pirazinas
WO2009117112A2 (en) 2008-03-21 2009-09-24 Novartis Ag Powder dispersion apparatus, method of making and using the apparatus, components that can be used on the apparatus and other devices, and various active agents
WO2009150137A2 (en) 2008-06-10 2009-12-17 Novartis Ag Organic compounds
JP2013508414A (ja) 2009-10-22 2013-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド 嚢胞性線維症および他の慢性疾患の治療のための組成物
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers

Also Published As

Publication number Publication date
PH12014502064A1 (en) 2014-12-10
SG11201405105TA (en) 2014-10-30
CA2865536A1 (en) 2013-09-26
KR20140122281A (ko) 2014-10-17
WO2013140319A1 (en) 2013-09-26
PL2828261T3 (pl) 2016-07-29
HRP20160420T1 (hr) 2016-05-20
EA201491719A1 (ru) 2015-01-30
DK2828261T3 (en) 2016-03-29
MX352185B (es) 2017-11-13
CL2014002339A1 (es) 2014-12-19
NZ629032A (en) 2016-03-31
AU2013237073A1 (en) 2014-09-25
HUE028761T2 (en) 2016-12-28
IN2014DN07461A (es) 2015-04-24
CN104302648A (zh) 2015-01-21
US8809340B2 (en) 2014-08-19
CA2865536C (en) 2020-06-02
EP2828261A1 (en) 2015-01-28
UA114904C2 (uk) 2017-08-28
EP2828261B1 (en) 2016-02-03
KR101686311B1 (ko) 2016-12-13
CN104302648B (zh) 2016-11-23
MX2014011294A (es) 2014-12-08
ECSP14023397A (es) 2015-11-30
SI2828261T1 (sl) 2016-05-31
US20130345239A1 (en) 2013-12-26
MA37391B1 (fr) 2017-02-28
JP2015510925A (ja) 2015-04-13
PE20142352A1 (es) 2015-01-14
JO3184B1 (ar) 2018-03-08
TWI608006B (zh) 2017-12-11
AU2013237073B2 (en) 2016-04-21
HK1200454A1 (zh) 2015-08-07
WO2013140319A9 (en) 2014-01-03
CY1117410T1 (el) 2017-04-26
GT201400200A (es) 2015-10-15
TW201343647A (zh) 2013-11-01
JP6134378B2 (ja) 2017-05-24
MY165082A (en) 2018-02-28
ZA201406238B (en) 2016-08-31
CO7071138A2 (es) 2014-09-30
ES2565811T3 (es) 2016-04-07
PH12014502064B1 (en) 2014-12-10
EA023716B1 (ru) 2016-07-29
MA37391A1 (fr) 2016-07-29
TN2014000369A1 (en) 2015-12-21

Similar Documents

Publication Publication Date Title
MX2020008468A (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CY1115043T1 (el) Φαρμακευτικο σκευασμα
UY35683A (es) Polimorfo de inhibidores de tirosina quinasa de bazo (syk)
NZ703162A (en) Heterocyclic modulators of lipid synthesis
CR20140301A (es) Derivados de betulina
MX2016006336A (es) Compuestos pirazolopirimidina.
HU1000069D0 (en) New salts for the preparation of pharmaceutical composition
AR092971A1 (es) Inhibidores de agrecanasa
AR095097A1 (es) Compuestos de fenoxietoxi
CU24293B1 (es) Procedimiento de preparación de la sal de l-arginina de perindoprilo
UY33864A (es) Novedoso Derivado Cristalino de Oxazina
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
CR20140325A (es) Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2-
AR090371A1 (es) Forma cristalina
HK1205095A1 (en) Methods and intermediates for preparing pharmaceutical agents
ECSP13012365A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación,
EA201200123A1 (ru) Новый способ синтеза ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
EA201100230A1 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
AR092627A1 (es) Derivados glucopiranosidos de urea
WO2014167509A3 (en) Loxoprofen polymorphs and process for preparation of the same
EA201300281A2 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
UA117655C2 (uk) Спосіб синтезу 3-(2-бромо-4,5-диметоксифеніл)пропаннітрілу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою
UA111156C2 (uk) Спосіб синтезу івабрадину і його адитивних солей з фармацевтично прийнятною кислотою
TR201106004A2 (tr) Sefalosporin türevinin farmasotik bir bileşim içerisinde kullanımı.

Legal Events

Date Code Title Description
FC Refusal